Serial changes of cerebral glucose metabolism and caudate size in persons at risk for huntington's disease

Archives of Neurology

Volumn 49, Issue 11, 1992, Pages 1161-1167

  Mazziotta, John C ^a   Baxter, Lewis R ^a   Phelps, Michael E ^a   Haines, Jonathan L ^b   Gusella, James ^b   Grafton, Scott T ^c   Pahl, Jorg J ^d   Hoffman, John M ^e   George Hyslop, Peter St ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

^e DUKE UNIVERSITY   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GLUCOSE;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; GENE LOCUS; GENETIC RISK; GLUCOSE METABOLISM; HUMAN; HUNTINGTON CHOREA; MEDICAL PRACTICE; NEUROANATOMY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; CAUDATE NUCLEUS; CEREBRAL CORTEX; DISEASE SUSCEPTIBILITY; FEMALE; GENETIC MARKERS; GLUCOSE; HUMAN; HUNTINGTON DISEASE; MALE; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0026475301     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1992.00530350075022     Document Type: Article

References (46)

1. Hayden MR. Huntington's Chorea. New York, NY: Springer-Verlag NY Inc, 1981.
2. Folstein SE, Leigh RJ, Parhad IM, Folstein MF. The diagnosis of Huntington's disease. Neurology. 1986;36:1279-1283.
3. Gusella JF, Wexler NS, Conneally PH, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983;306:234-238.
4. Hayden MR, Hewitt J, Stoessl AJ, Clark C, Ammann W, Martin WRW. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease. Neurology. 1987;37:1441-1447.
5. Kuhl DE, Phelps ME, Markham CH, Metter JE, Riege WH, Winter J. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scans. Ann Neurol. 1982;12:425-434.
6. Mazziotta JC, Phelps ME, Pahl JJ, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med. 1987;316:357-362.
7. Hayden MR, Martin WR, Stoessl AJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology. 1986;36:888-894.
8. Grafton ST, Mazziotta JC, Pahl JJ, et al. A comparison of neurologic, metabolic, structural and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol. 1990;28:614-621.
9. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985;44:559-577.
10. Myers R, Vonsattel J, Steven T, et al. Clinical and neuropathologic assessement of severity in Huntington's disease. Neurology. 1988;38:341-347.
11. Harris GJ, Pearlson GD, Peyser CE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol. 1992;31:69-75.
12. Perry TL, Hansen S. What excititoxin kills striatal neurons in Huntington's disease? clues from neurochemical studies. Neurology. 1990;40:20-24.
13. Albin RL, Qin Y, Young AB, Penney JB, Chesselet M-F. Prepronkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington's disease: An in situ hybridization study. Ann Neurol. 1991;30:542-549.
14. Myers RH, Sax DS, Schoenfeld M, et al. Late onset of Huntington's disease. J Neurol Neurosurg Psychiatry. 1985;48:530-534.
15. Sax DS, Bird ED, Gusella JF, Myers RH. Phenotypic variation in 2 Huntington's disease families with linkage to chromosome 4. Neurology. 1989;39:1332-1336.
16. Conneally P. Huntington's disease: genetics and epidemiology. Am J Hum Genet. 1984;36:506-526.
17. Adams P, Falek A, Arnold J. Huntington disease in Georgia: Age at onset. Am J Hum Genet. 1988;43:695-704.
18. Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-388.
19. Hoffman EJ, Phelps ME, Huang SC. Performance evaluation of a positron tomograph designed for brain imaging. J Nucl Med. 1983;24:245-257.
20. Huang SC, Carson RE, Phelps ME, Hoffman EJ, Schelbert HR, Kuhl DE. A boundary method for attenuation correction in positron computed tomography. J Nucl Med. 1981;22:627-637.
21. Mazziotta JC, Phelps ME, Plummer D, Kuhl DE. Quantitation in positron emission computed tomography, V: physical-anatomical effects. J Comput Assist Tomogr. 1981;5:734-743.
22. Mazziotta JC, Phelps ME, Plummer D. Optimization and standardization of anatomical data in neurobehavioral investigations using positron CT. J Cereb Blood Flow Metab. 1983;3:S266-S267.
23. Grady CL. Quantitative comparison of measurements of cerebral glucose metabolic rate made with two positron cameras. J Cereb Blood Flow Metab. 1991;11:A57-A63.
24. Reivich M, Alavi A, Wolf A, et al. Use of 2-Deoxy-D[1-11C]glucose for the determination of local cerebral glucose metabolism in humans: variation within and between subjects. J Cereb Blood Flow Metab. 1982;2:307-319.
25. de Leon MJ, Ferris SH, George AE, et al. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab. 1983;3:391-394.
26. Cutler NR, Duara R, Creasey H, et al. Brain imaging: Aging and dementia. Ann Intern Med. 1984;101:355-369.
27. Duara M, Grady C, Haxby J, et al. Human brain glucose utilization and cognitive function in relation to age. Ann Neurol. 1984;16:702-713.
28. Brooks RA, Di Chiro G, Zukerberg BW, Bairamian D, Larson SM. Test-retest studies of cerebral glucose metabolism using fluorine-18 deoxyglucose: validation of method. J Nucl Med. 1987;28:53-59.
29. Bartlett EJ, Brodie JD, Wolf AP, Christman DR, Laska E, Morris M. Reproducibility of cerebral glucose metabolic measurements in resting human subjects. J Cereb Blood Flow Metab. 1988;8:502-512.
30. Tyler J, Strother S, Zatorre R, et al. Stability of regional cerebral glucose metabolism in the normal brain measured by positron emission tomography. J Nucl Med. 1988;29:631-642.
31. Yoshii F, Barker WW, Chang JY, et al. Sensitivity of cerebral glucose metabolism to age, gender, brain volume, brain atrophy, and cerebrovascular risk factors. J Cereb Blood Flow Metab. 1988;8:654-661.
32. Stober T, Wussow W, Schimrigk K. Bicaudate diameter—the most specific and simple CT parameter in the diagnosis of Huntington's disease. Neuroradiology. 1984;26:25-28.
33. MacDonald ME, Haines JL, Zimmer M, et al. Recombination events suggest potential sites for the Huntington's disease gene. Neuron. 1989;3:183-190.
34. Lathrop GM, Laloouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci U S A. 1984;81:3443-3446.
35. Young A, Shoulson I, Penney J, et al. Huntington's disease in Venezuela: neurological features and functional decline. Neurology. 1986;36:244-249.
36. Kuwert T, Lange HW, Langen K-J, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain. 1990;113:1405-1423.
37. Martin WRW, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR. Cortical glucose metabolism in Huntington's disease. Neurology. 1992;42:223-229.
38. Clark C, Hayden MR, Stoessl AJ, Martin WRW. Regression model for predicting dissociations of regional cerebral glucose metabolism in individuals at risk for Huntington's disease. J Cereb Blood Flow Metab. 1986;6:756-762.
39. Farrar LA, Conneally PM. Predictability of phenotype in Huntington's disease. Arch Neurol. 1987;44:109-113.
40. Sax DS, Bird ED, Gusella JF, Myers RH. Phenotypic variation in two Huntington's disease families with linkage to chromosome 4. Neurology. 1989;39:1332-1336.
41. Young AB, Penney JB, Starosta-Rubinstein S, et al. Normal caudate glucose metabolism in persons at risk for Huntington's Disease. Arch Neurol. 1987;44:254-257.
42. Hayden MR, Hewitt J, Martin WRW, Clark C, Ammann W. Studies in persons at risk for Huntington's disease. N Engl J Med. 1987;317:382-383.
43. Perlmutter JS, Raichle ME. Studies in persons at risk for Huntington's disease. N Engl J Med. 1987;31 7:383.
44. Mazziotta JC, Phelps ME, Pahl JJ, et al. Studies in persons at risk for Huntington's disease. N Engl J Med. 1987;317:383-384.
45. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol. 1989;25:252-259.
46. Rosner B. Fundamentals of Biostatistics. Boston, Mass: Duxbury Press; 1986.